Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

CHAM3 induces clinical and biological improvement in HIV patients

July 26, 1996

ZY-1 demonstrates therapeutic promise in HIV patients

July 26, 1996

TAR-PAK-140: University of Alberta's anti-HIV vector

July 26, 1996

Mulsal N shows significant CD4 cell count increases in trial

July 26, 1996

Virulizin enters phase I/II for drug-resistant HIV-related Kaposi's sarcoma

July 26, 1996

Columbia Laboratories' SPC3 undergoes phase I/II trials

July 26, 1996

Allophenylnorstatine HIV protease inhibitors described

July 26, 1996

Sequus licenses liposome-CD4 technology

July 26, 1996

Gilead Science's sulfone HIV protease inhibitors

July 26, 1996

Positive phase I/II results for PDT's SnET2 in AIDS-associated Kaposi's sarcoma patients

July 19, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...